Table 4 |
||
|
Scores by item of the AGREE instrument |
||
| Domains and items of the AGREE instrument |
Median value |
Interquartile range |
|
|
||
| Domain 1: Scope and purpose |
||
| 1. The overall objective(s) of the guideline is (are) specifically described |
1.5 |
1.5 |
| 2. The clinical question(s) covered by the guideline is (are) specifically described |
2 |
1 |
| 3. The patients to whom the guideline is meant to apply are specifically described |
2.5 |
1.5 |
| Domain 2: Stakeholder involvement |
||
| 4. The guideline development group includes individuals from all the relevant professional
groups |
1.5 |
1 |
| 5. The patients' views and preferences have been sought |
1 |
0.5 |
| 6. The target users of the guideline are clearly defined |
1 |
1 |
| 7. The guideline has been piloted among end users |
1 |
0 |
| Domain 3: Rigour of development |
||
| 8. The systematic methods were used to search for evidence |
1 |
0 |
| 9. The criteria for selecting the evidence are clearly described |
1 |
0 |
| 10. The methods used for formulating the recommendations are clearly described |
1.5 |
0.5 |
| 11. The health benefits, side effects and risks have been considered in formulating
the recommendations |
2 |
1 |
| 12. There is an explicit link between the recommendations and the supporting evidence |
1 |
1 |
| 13. The guideline has been externally reviewed by experts prior to its publication |
1 |
0.5 |
| 14. A procedure for updating the guideline is provided |
1 |
0 |
| Domain 4: Clarity and presentation |
||
| 15. The recommendations are specific and unambiguous |
2.5 |
1.5 |
| 16. The different options for management of the condition are clearly presented |
2.5 |
1.5 |
| 17. Key recommendations are easily identifiable |
2.5 |
1.5 |
| 18. The guideline is supported with tools for application |
1 |
0.5 |
| Domain 5: Applicability |
||
| 19. The potential organizational barriers in applying the recommendations have been
discussed |
1 |
0.5 |
| 20. The potential cost implications of applying the recommendations have been considered |
1 |
0 |
| 21. The guideline presents key review criteria for monitoring and/or audit purposes |
1 |
1 |
| Domain 6: Editorial independence |
||
| 22. The guideline is editorially independent from the funding body |
1 |
0 |
| 23. Conflicts of interest of guideline development members have been recorded |
1 |
0 |
|
|
||
|
Esandi et al. Implementation Science 2008 3:43 doi:10.1186/1748-5908-3-43 |
||
